Price Performance Outpaces Benchmarks
The stock closed at ₹703.00 on 22 Jun 2026, marking a substantial 19.69% gain on the day and nearing its 52-week high of ₹704.80. This rally has propelled Shree Ganesh Remedies to deliver a year-to-date return of 51.77%, vastly outperforming the Sensex’s negative 9.88% return over the same period. Over longer horizons, the stock’s 3-year and 5-year returns stand at 98.7% and 112.39% respectively, dwarfing the Sensex’s 21.58% and 46.73% gains. This outperformance underscores strong investor appetite despite the stock’s micro-cap status and elevated valuation.
Valuation Metrics Reflect Elevated Price Levels
Shree Ganesh Remedies’ current P/E ratio stands at 50.79, a marked increase that has shifted its valuation grade from expensive to very expensive. This P/E is notably higher than several peers in the Pharmaceuticals & Biotechnology sector, including Bliss GVS Pharma (P/E 39.37), Kwality Pharma (38.01), and Venus Remedies (23.01). The company’s price-to-book value ratio of 5.54 further accentuates the premium investors are willing to pay, compared to peers such as Fredun Pharma, which is considered attractive despite a P/E of 38.55.
Enterprise value multiples also reflect this premium stance. The EV/EBITDA ratio of 25.89 is elevated relative to the sector average, with competitors like Venus Remedies and Fredun Pharma trading at 15.45 and 16.89 respectively. The EV/EBIT ratio of 36.93 and EV to capital employed of 5.41 reinforce the expensive valuation narrative. These multiples suggest that the market is pricing in strong growth expectations and operational efficiency improvements.
Operational Efficiency and Returns
Despite the lofty valuation, Shree Ganesh Remedies demonstrates respectable operational metrics. The latest return on capital employed (ROCE) is 14.64%, while return on equity (ROE) stands at 10.90%. These figures indicate moderate profitability and capital utilisation, though they are not exceptionally high to fully justify the valuation premium. Investors should weigh these returns against the elevated multiples to assess the sustainability of current price levels.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Comparative Valuation Within the Sector
When benchmarked against its peer group, Shree Ganesh Remedies’ valuation stands out as one of the highest. The company’s P/E ratio of 50.79 exceeds that of Shukra Pharma (50.39) and Jagsonpal Pharma (31.53), both also rated very expensive. Meanwhile, companies like Syncom Formulations trade at a more reasonable P/E of 17.2, classified as fair value. The PEG ratio of Shree Ganesh Remedies is reported as zero, which may indicate either a lack of earnings growth data or an anomaly, contrasting with peers whose PEG ratios range from 0.13 to 1.97, signalling varying degrees of growth expectations relative to price.
Market Capitalisation and Risk Profile
Shree Ganesh Remedies is classified as a micro-cap stock, which inherently carries higher volatility and liquidity risk. The recent upgrade in its Mojo Grade from Sell to Hold on 20 May 2026, with a current Mojo Score of 58.0, reflects a cautious optimism among analysts. This rating suggests that while the stock shows potential, investors should remain vigilant given the stretched valuation and micro-cap status.
Price Momentum and Volatility
The stock’s day range on 22 Jun 2026 was ₹614.95 to ₹704.80, indicating significant intraday volatility. The sharp 19.69% day gain is a testament to strong buying interest, possibly driven by positive sentiment or news flow. However, such volatility also implies risk for short-term traders and highlights the importance of a disciplined investment approach.
Shree Ganesh Remedies Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Historical Valuation Context
Historically, Shree Ganesh Remedies traded at lower valuation multiples, with the recent surge pushing it into very expensive territory. The P/E ratio has climbed well above the sector median, reflecting heightened investor expectations for earnings growth or strategic developments. However, the absence of dividend yield data and a PEG ratio of zero warrant caution, as these factors may indicate limited current earnings growth visibility or payout capacity.
Investor Takeaway
Investors considering Shree Ganesh Remedies must balance the stock’s impressive price appreciation and sector outperformance against its stretched valuation metrics and micro-cap risks. The upgrade to a Hold rating suggests that while the stock is no longer a sell, it may not offer compelling value at current levels. Prospective buyers should monitor operational performance, earnings growth, and sector dynamics closely before committing capital.
Conclusion
Shree Ganesh Remedies Ltd’s valuation shift from expensive to very expensive is a clear signal of changing market sentiment and elevated expectations. While the company’s operational returns are moderate, the premium multiples reflect optimism about future prospects. Given the stock’s micro-cap classification and volatility, a cautious approach is advisable, with investors encouraged to consider alternative opportunities within the Pharmaceuticals & Biotechnology sector that may offer better risk-adjusted returns.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
